OTCMKTS:BIXT Bioxytran (BIXT) Stock Price, News & Analysis $0.12 +0.01 (+7.73%) As of 06/24/2025 03:59 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsHeadlinesSEC FilingsShort InterestBuy This Stock About Bioxytran Stock (OTCMKTS:BIXT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Bioxytran alerts:Sign Up Key Stats Today's Range$0.10▼$0.1250-Day Range$0.10▼$0.1852-Week Range$0.06▼$0.23Volume89,868 shsAverage Volume145,178 shsMarket Capitalization$10.54 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewBioxytran, Inc., a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans. The company's lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing. It is also developing ProLectin-Rx, a polysaccharide derived from pectin that binds to, and blocks the activity of galectin-1, a type of galectin for treatment of mild to moderate cases of Covid-19. The company was founded in 2008 and is headquartered in Needham, Massachusetts.Read More… Bioxytran Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks4th Percentile Overall ScoreBIXT MarketRank™: Bioxytran scored higher than 4% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Bioxytran. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Bioxytran is -3.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Bioxytran is -3.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.01% of the float of Bioxytran has been sold short.Short Interest Ratio / Days to CoverBioxytran has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous month Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBioxytran does not currently pay a dividend.Dividend GrowthBioxytran does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.01% of the float of Bioxytran has been sold short.Short Interest Ratio / Days to CoverBioxytran has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous month News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Bioxytran this week, compared to 0 articles on an average week. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Bioxytran insiders have not sold or bought any company stock.Percentage Held by Insiders70.00% of the stock of Bioxytran is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about Bioxytran's insider trading history. Receive BIXT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bioxytran and its competitors with MarketBeat's FREE daily newsletter. Email Address BIXT Stock News HeadlinesBioxytran Secures a Source of GMP Quality Camel HemoglobinJune 18, 2025 | globenewswire.comBioxytran’s Groundbreaking Stroke & Alzheimer’s Tech Gains Validation That Measures Oxygenation Uptake During StrokesJune 3, 2025 | finance.yahoo.comA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. June 25, 2025 | Porter & Company (Ad)Bioxytran's Groundbreaking Stroke & Alzheimer's Tech Gains Validation That Measures Oxygenation Uptake During StrokesJune 3, 2025 | globenewswire.comBioxytran’s Antiviral Breakthrough Featured in University of Georgia’s $100M HPAI Poultry Innovation Grand Challenge SubmissionMay 21, 2025 | finance.yahoo.comBioxytran's Antiviral Breakthrough Featured in University of Georgia's $100M HPAI Poultry Innovation Grand Challenge SubmissionMay 21, 2025 | globenewswire.comBIOXYTRAN, INC.: Bioxytran Completes Dose Optimization of Antiviral, ProLectin-MMay 12, 2025 | finanznachrichten.deBioxytran Completes Dose Optimization of Antiviral, ProLectin-MMay 12, 2025 | globenewswire.comSee More Headlines BIXT Stock Analysis - Frequently Asked Questions How have BIXT shares performed this year? Bioxytran's stock was trading at $0.0899 at the beginning of 2025. Since then, BIXT stock has increased by 31.7% and is now trading at $0.1184. View the best growth stocks for 2025 here. How were Bioxytran's earnings last quarter? Bioxytran, Inc. (OTCMKTS:BIXT) announced its quarterly earnings results on Thursday, May, 15th. The company reported ($0.02) earnings per share (EPS) for the quarter. How do I buy shares of Bioxytran? Shares of BIXT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Bioxytran own? Based on aggregate information from My MarketBeat watchlists, some other companies that Bioxytran investors own include AMC Entertainment (AMC), Armata Pharmaceuticals (ARMP), bluebird bio (BLUE), Esports Entertainment Group (GMBL), Genius Group (GNS), Novavax (NVAX) and Karora Resources Inc. (RNX.TO) (RNX). Company Calendar Last Earnings5/15/2025Today6/25/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:BIXT CIK1445815 Webwww.bioxytraninc.com Phone(617) 454-1199FaxN/AEmployees2Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.03) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$2.37 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-2,077.16% Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.02) per share Price / Book-5.92Miscellaneous Outstanding Shares88,990,000Free Float26,698,000Market Cap$10.54 million OptionableNot Optionable Beta1.78 10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free Report This page (OTCMKTS:BIXT) was last updated on 6/25/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bioxytran, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bioxytran With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.